IFNG and neoplasm: Therefore, we investigated whether RdB/IL12/GMCSF-RLX + ICI, which produced markedly higher amounts of most representative Th1 type cytokine (IL-12 and IFN-γ) than any other treatment group, could shift the tumor microenvironment from Th2 to Th1 immunity.